ANXA2 and neoplasm: This protein has high affinity for binding to annexin A2 (ANXA2) 44 and RAGE receptors 5, 45, activating the Wnt/β-catenin signalling pathway, contributing to oncogenesis, metastasis, tumor progression and drug resistance 42, 46.